{"brief_title": "Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer", "brief_summary": "The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.", "condition": ["Kidney Neoplasms"], "intervention_type": ["Drug"], "intervention_name": ["SU-011,248"], "criteria": "Inclusion Criteria: - Eligible patients must be at least 18 years of age with a diagnosis of metastatic kidney cancer. - The patient's kidney cancer must have gotten worse during/after previous cytokine-based therapy was given. - Any side effects from prior therapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function Exclusion Criteria: - Prior treatment with any systemic therapy other than 1 prior cytokine-based treatment regimen; - Prior surgical resection of or irradiation to the only site of measurable disease; - Ongoing severe hematuria; - Other active second malignancy; - Cardiovascular diseases or conditions within the last 12 months; - Known brain metastases; - Known HIV-positive or AIDS-related illness; - Pregnant or breast-feeding women; - Current participation in other clinical trials; - Other severe acute or chronic medical conditions.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Kidney Neoplasms", "Sunitinib"], "id": "NCT00054886"}